Cancel
Exogene
See Linkedin
Exogene Employees
8 people indexed:
-
l.39fjsvw4@pps52d9.j3.y3 Sign up to see email
-
9.lp5qq2@h40bw5v.5h.21 Sign up to see email
-
j.qzq380rh@s32yyw5.w8.mb Sign up to see email
-
7.wb096t0h@03546rl.rt.bd Sign up to see email
-
8.vl1h190@3f5yt30.7h.42 Sign up to see email
-
6.8j793@1f9dtf1.4w.w3 Sign up to see email
-
y.jvjqqmmq4@a22za9w.1t.zp Sign up to see email
-
p.fz7myl@m8011t1.2m.5t Sign up to see email
Exogene Company Information
Exogene is a biotechnology company that specializes in the use of deep learning to advance the discovery and development of TCR-based therapies aimed at treating cancer. The company’s generative AI platform is designed to perform comprehensive mining of the TCR sequence space, enabling the discovery of novel, high-affinity, and non-cross-reactive TCRs that target antigens shared across different patients and tumor types. Exogene’s efforts are particularly focused on eradicating solid tumors. The company has entered into a research collaboration with Immunocore, aiming to rapidly enhance the affinity of TCRs using its AI-enabled platform. Exogene has been featured in the BioInnovator Spotlight podcast, where it discussed its foundation and its aspirations to innovate T-cell receptor-based cancer immunotherapies using artificial intelligence. Additionally, the company has been highlighted in Global Roundup for securing funding to support its TCR discovery efforts and discussed in Nature magazine regarding how AI is revolutionizing T cell receptor screening for cell therapy discovery. Exogene’s partners include notable organizations such as Entrepreneur First, Creative Destruction Lab, R42 Group, The Francis Crick Institute, Selvedge Venture, and LifeArc.
Report inaccurate information
Report inaccurate information
